EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieKohortenstudie

Effectiveness of Mepolizumab and Dupilumab in patients with asthma-COPD overlap (ACO) compared to severe uncontrolled asthma (SUA): A retrospective observational cohort study

Belén Muñoz-Sánchez, Antonio León-Lloreda, David Carlos Echavarría, María Polonio-González, Juan Francisco Medina-Gallardo, Marta Ferrer-Galván, Auxiliadora Romero-Falcón, Javier Díez-Sierra, Francisco Javier Álvarez-Gutiérrez

Pulmonary Pharmacology & Therapeutics · 2026

DOI: 10.1016/j.pupt.2025.102407 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2026. Verfasst von Belén Muñoz-Sánchez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Virgen del Rocío, Sevilla, Spain. Electronic address: belen.munoz.sanchez.sspa@juntadeandalucia.es. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Anti-Asthmatic Agents, Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The coexistence of asthma and chronic obstructive pulmonary disease (COPD), known as asthma-COPD overlap (ACO), presents unique diagnostic and therapeutic challenges. Although biological therapies such as Mepolizumab and Dupilumab have transformed the management of severe eosinophilic asthma, their role in ACO remains poorly defined due to the exclusion of this phenotype from most clinical trials. METHODS: This retrospective observational study aimed to evaluate the real-world effectiveness of Mepolizumab and Dupilumab in patients with ACO compared to those with severe uncontrolled asthma (SUA). We included 212 patients treated in a specialized asthma unit between 2017 and 2024, all with at least 12 months of follow-up. Treatment response was assessed using clinical tools (EXACTO scale and SEPAR-REMAS criteria). RESULTS: Among Mepolizumab-treated patients (ACO n = 10; SUA n = 132), those with ACO had significantly lower baseline FEV1 and lower rates of good/complete response (14.2 % vs. 60 %, p < 0.03) and clinical remission (0 % vs. 20.9 %). In the Dupilumab group (ACO n = 10; SUA n = 60), ACO patients showed lower baseline ACT scores and FEV1, with reduced response rates (25 % vs. 55 %) and no clinical remission, although differences were not statistically significant. Despite limited power due to small ACO sample sizes, the magnitude of these differences suggests a clinically relevant reduction in biologic effectiveness in ACO. CONCLUSION: These findings emphasize the urgent need for dedicated studies in ACO, a population with a high disease burden and limited treatment guidance. Individualized therapeutic approaches should be prioritized until robust clinical trial data becomes available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaAnti-Asthmatic AgentsAsthma-Chronic Obstructive Pulmonary Disease Overlap SyndromePulmonary Disease, Chronic ObstructiveHumansRetrospective StudiesFemaleMaleMiddle AgedTreatment OutcomeSeverity of Illness IndexAgedCohort StudiesFollow-Up Studies

Stichwörter der Autor:innen

AsthmaBiologic therapyChronic obstructive pulmonary disease (COPD)Clinical remissionReal-world studyTherapeutic response

Substanzen

Antibodies, Monoclonal, HumanizedmepolizumabdupilumabAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Hospital Universitario Virgen del Rocío, Sevilla, Spain. Electronic address: belen.munoz.sanchez.sspa@juntadeandalucia.es.
  • Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Zitieren

APA

Muñoz-Sánchez, B., León-Lloreda, A., Echavarría, D. C., Polonio-González, M., Medina-Gallardo, J. F., Ferrer-Galván, M., Romero-Falcón, A., Díez-Sierra, J., & Álvarez-Gutiérrez, F. J. (2026). Effectiveness of Mepolizumab and Dupilumab in patients with asthma-COPD overlap (ACO) compared to severe uncontrolled asthma (SUA): A retrospective observational cohort study. Pulmonary Pharmacology & Therapeutics. https://doi.org/10.1016/j.pupt.2025.102407

Vancouver

Muñoz-Sánchez B, León-Lloreda A, Echavarría DC, Polonio-González M, Medina-Gallardo JF, Ferrer-Galván M, et al. Effectiveness of Mepolizumab and Dupilumab in patients with asthma-COPD overlap (ACO) compared to severe uncontrolled asthma (SUA): A retrospective observational cohort study. Pulmonary Pharmacology & Therapeutics. 2026. doi:10.1016/j.pupt.2025.102407

BibTeX
@article{MuozSnchez2026,
  author = {Muñoz-Sánchez, Belén and León-Lloreda, Antonio and Echavarría, David Carlos and Polonio-González, María and Medina-Gallardo, Juan Francisco and Ferrer-Galván, Marta and Romero-Falcón, Auxiliadora and Díez-Sierra, Javier and Álvarez-Gutiérrez, Francisco Javier},
  title = {Effectiveness of Mepolizumab and Dupilumab in patients with asthma-COPD overlap (ACO) compared to severe uncontrolled asthma (SUA): A retrospective observational cohort study},
  journal = {Pulmonary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1016/j.pupt.2025.102407}
}
Kostenlos starten →